KPRX vs ASNS Comparison

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Actelis Networks Inc is a networking solutions company with a mission to enable communication for Internet of Things, or IoT, projects, deployed over wide areas such as cities, campuses, airports, military bases, roads, and rail. Its networking solutions use a combination of newly deployed fiber infrastructure and existing copper and coaxial lines to create a cost-effective, secure, and quick-to-deploy network. Its solutions also offer end-to-end network security to protect critical IoT data, utilizing a powerful combination of coding and encryption technologies, applied as required on both new and existing infrastructure within the hybrid-fiber-copper network. The company operates as one operating segment: developing and marketing access broadband equipment for copper and fiber networks.